Non-Small Cell Lung Cancer
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Articles about Non-Small Cell Lung Cancer
Showing 1–6 of 6 articles
Quick answer
NovaPharmaNews Non-Small Cell Lung Cancer hub for EMA covers 6 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Nuvation Bio's IBTROZI Generates $18.5M Revenue in Q1 2026, Shows Strong First-Line Adoption in ROS1+ NSCLC
Treatment Sequencing in NSCLC: Insights from EU Guidelines and ESMO
Beamion's Zongertinib Receives FDA Accelerated Approval for HER2-Mutant NSCLC as LUNG-1 Study Results Published in NEJM
TRI-611 Receives FDA Fast Track Designation for ALK-Positive Non-Small Cell Lung Cancer as Competition Intensifies
EMA Backs Amgen's Tarlatamab as First-in-Class BiTE Therapy for Advanced Small Cell Lung Cancer
EMA Recommends First Bispecific T-Cell Engager for Relapsed Small Cell Lung Cancer
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.